S-1/A: BioVie Inc. Launches $13.5M Public Offering Amidst Clinical Trial Setbacks and Going Concern Warning

BioVie Inc. announced a public offering to raise approximately $13.5 million for working capital, while grappling with significant clinical trial integrity issues, ongoing litigation, and a 'going concern' warning despite reduced net losses.

Summary

• BioVie Inc. is conducting a firm commitment underwritten public offering of 1,456,310 units (common stock + warrant) and 1,456,310 pre-funded units (pre-funded warrant + warrant) at an assumed public offering price of $10.30 per unit, aiming to raise approximately $13.5 million in net proceeds.
• The company is a clinical-stage biopharmaceutical firm focusing on neurological/neurodegenerative disorders (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease (ascites).
• Net loss significantly decreased to $2.8 million for the three months ended March 31, 2025, from $8.1 million in the prior year, and to $14.1 million for the nine months ended March 31, 2025, from $27.2 million.
• Research and development expenses decreased by $4.4 million for the three months ended March 31, 2025, and by $13.0 million for the nine months ended March 31, 2025, primarily due to the completion of prior clinical trials and a reduction in force.
• The Phase 3 Alzheimer's trial for bezisterim (NE3107) was underpowered due to significant protocol deviations and cGCP violations at 15 study sites, leading to patient exclusions and referral to the FDA Office of Scientific Investigations (OSI).
• A new Phase 2b study for bezisterim in new onset Parkinson's disease commenced in April 2025, following FDA permission in July 2024.
• The Phase 2 ADDRESS-LC study for bezisterim in Long COVID, fully funded by a $13.1 million DOD grant, commenced in May 2025. The company was reimbursed $2.9 million for trial costs through March 31, 2025.
• For BIV201 in liver cirrhosis, the company is finalizing the protocol design for a Phase 3 study targeting a broader ascites patient population, following FDA guidance in June 2023 and December 2024.
• The company faces substantial doubt about its ability to continue as a going concern due to recurring losses and negative cash flows, necessitating additional financing.
• Ongoing shareholder class action and derivative lawsuits allege material misrepresentations related to the Alzheimer's trial, with a motion to dismiss denied in March 2025, moving to fact discovery.
• A 1-for-10 reverse stock split became effective on July 7, 2025, approved by the Board on June 26, 2025, and stockholders on June 23, 2025.

Sentiment

Score: 3

Explanation: While the company has reduced its net loss and secured a significant grant for its Long COVID program, the severe issues with the Alzheimer's Phase 3 trial (cGCP violations, underpowered), ongoing litigation, and explicit 'going concern' warning present significant red flags. The capital raise is necessary but also highlights the precarious financial position and will cause further dilution.

Positives

• Net loss significantly decreased by $5.3 million for the three months ended March 31, 2025, and by $13.1 million for the nine months ended March 31, 2025, compared to the prior year periods.
• Research and development expenses decreased by $4.4 million for the three months and $13.0 million for the nine months ended March 31, 2025, primarily due to the completion of certain clinical trials and a reduction in force.
• A new Phase 2b study for bezisterim in new onset Parkinson's disease commenced in April 2025, following FDA permission in July 2024.
• The Phase 2 ADDRESS-LC study for bezisterim in Long COVID is fully funded by a $13.1 million grant from the U.S. Department of Defense, reducing the company's financial burden for this program.
• Preliminary efficacy signals were observed in the per-protocol population of the underpowered Phase 3 Alzheimer's trial for bezisterim, suggesting a slowing of cognitive loss and age deceleration.
• BIV201 has received FDA Fast Track and Orphan Drug designations for ascites and hepatorenal syndrome, which could expedite development and provide market exclusivity.
• Phase 2 data for BIV201 showed a 30% reduction in ascites fluid during treatment and a 53% reduction sustained (43% at three months) in completed patients, with a significant difference from standard-of-care.
• The proprietary room-temperature stable liquid formulation of BIV201 offers a key product differentiation compared to other terlipressin products globally that require refrigeration and are not available in pre-filled syringe format.

Negatives

• The Phase 3 Alzheimer's trial for bezisterim was significantly underpowered for its primary endpoints due to the exclusion of patients from 15 study sites (virtually all from one geographic area) because of significant protocol deviations and current good clinical practices (cGCP) violations.
• The company referred the problematic study sites to the FDA Office of Scientific Investigations (OSI) for potential further action, indicating serious issues with data integrity and trial conduct.
• The company has no products approved for commercial sale and has never generated any revenues, raising substantial doubt about its ability to continue as a going concern.
• Ongoing shareholder class action and derivative lawsuits allege material misrepresentations related to the Alzheimer's trial, which could result in substantial damages and divert significant management resources.
• The company has limited experience in drug development and manufacturing, relying heavily on third parties, which introduces significant operational and regulatory risks.
• The 1-for-10 reverse stock split has caused a decline in the value of outstanding common stock and may further decrease liquidity.
• The company will need to raise substantial additional capital in the future, which could lead to significant dilution for existing stockholders.
• The company has an accumulated deficit of approximately $348.7 million as of March 31, 2025.

Risks

• Reliance on third-party contractors (CROs, clinical trial sites, manufacturers) to conduct clinical trials, with risks of non-compliance, missed deadlines, and data integrity issues.
• High uncertainty in biopharmaceutical development; product candidates may fail in later stages, be less effective, have harmful side effects, or fail to receive regulatory approvals.
• Concentration of cash assets in a single financial institution exposes the company to liquidity risks in case of bank failures.
• Ongoing securities class action and derivative litigation could result in significant legal expenses, management distraction, and unfavorable outcomes, including substantial damages.
• No approved products or revenues to date, and no assurance of future profitability, which could lead to cessation of operations.
• Limited operating history as a development-stage company, making business evaluation difficult.
• Risk of generic versions of approved products or insufficient exclusivity periods adversely affecting sales.
• Failure to obtain or maintain Orphan Drug exclusivity for BIV201 could reduce competitive advantage.
• Need to raise substantial additional capital, which may not be available on acceptable terms and could cause significant stockholder dilution or force program delays/terminations.
• Limited experience in drug development and manufacturing, increasing risk of failure.
• Development of pharmaceutical products is time-consuming and subject to factors outside of control, leading to potential delays or abandonment.
• Risk of expending limited resources on less profitable or less successful drug candidates/indications.
• Failure to comply with manufacturing regulations (cGMP) could prevent product sales.
• Lack of internal sales and marketing personnel, requiring reliance on third parties.
• Business disruption and related risks from potential future pandemics.
• Loss or unavailability of key management personnel could create a competitive disadvantage.
• Inability to attract and retain highly skilled personnel.
• Inability to compete with larger, better-resourced biotechnology and biopharmaceutical companies.
• Conflicts of interest among officers, directors, and stockholders.
• Indemnification of officers and directors could increase operating costs.
• Inability to obtain or protect intellectual property rights, including challenges to patents, and potential disclosure of trade secrets.
• Failure to comply with licensing and collaboration agreements could harm competitive position.
• Intellectual property discovered through government funding may be subject to march-in rights and U.S.-based manufacturing preferences.
• Patent terms may be inadequate to establish a competitive position for a sufficient time.
• Inability to protect intellectual property rights globally due to varying laws and enforcement.
• Changes in patent law could diminish patent value.
• Involvement in intellectual property lawsuits, which are expensive, time-consuming, and may be unsuccessful.
• Risk of third parties alleging infringement of their intellectual property rights.
• Claims challenging inventorship of patents.
• Intellectual property rights may not address all potential threats.
• Intellectual property litigation may lead to unfavorable publicity and stock price decline.
• Immediate and substantial dilution for new investors from the public offering.
• Management's broad discretion over use of proceeds may not yield significant returns or align with investor expectations.
• Stock price volatility and low trading volume, making it difficult to resell shares.
• Risk of Nasdaq delisting if the offering does not qualify as a public offering under stockholder approval rules.
• No intention to pay dividends, limiting returns to stock appreciation.
• Future dilution from equity offerings, options, warrants, or milestone-based share issuances.
• No established public trading market for Pre-funded Warrants or Warrants.
• Pre-funded Warrants and Warrants are speculative and may have no value in bankruptcy.
• Failure to maintain effective internal control over financial reporting.
• Lack of public company experience of management team.
• Exemption from certain disclosure requirements as a smaller reporting company may make stock less attractive.
• Costs associated with periodic reporting requirements.
• Authorization to issue blank check preferred stock without stockholder approval could adversely impact common stockholders.
• Anti-takeover provisions in corporate documents and Nevada law.

Future Outlook

The company intends to use the net proceeds from the current offering for working capital and general corporate purposes, including capital expenditures, research and development, and potential acquisitions. Future operations are dependent on the success of ongoing development and commercialization efforts and the ability to secure additional financing. The company is considering continuing enrollment in the Alzheimer's disease Phase 3 trial via an adaptive feature or designing a new Phase 3 study for bezisterim in Alzheimer's disease. It is also finalizing the protocol design for a Phase 3 study of BIV201 for ascites.

Management Comments

• "We are a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease."
• "BioVie believes that bezisterim may offer clinical improvements in several disease indications, including PD, AD and long COVID."
• "The Company designed a new Phase 2b study of bezisterim as a potential first line therapy to treat patients with new onset PD."
• "The Company anticipates the trial [Long COVID] to commence in May 2025."
• "We believe BIV201 (continuous infusion terlipressin) has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis..."
• "Management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions."
• "The Company believes that the claims [shareholder class action] are without merit and intend to defend vigorously against them..."

Industry Context

The company operates in the highly competitive biotechnology and biopharmaceutical industries, characterized by rapid technological developments. It faces competition from well-established pharmaceutical companies and academic institutions. Its drug candidates target significant unmet medical needs in Alzheimer's disease (estimated 6 million Americans), Parkinson's disease (estimated 1 million Americans), and Long COVID (approximately 20 million adults in the U.S.), and ascites (a market estimated to exceed $650 million). The Alzheimer's and Parkinson's disease fields have major competitors such as Biogen and Eli Lilly, while the ascites market currently has no FDA-approved drug specifically for the condition, though other companies are developing therapies for severe complications of liver cirrhosis.

Comparison to Industry Standards

• The Alzheimer's disease Phase 3 trial for bezisterim was originally designed to be 80% powered with 125 patients in each arm, which is a standard power for Phase 3 trials, but the exclusion of 15 sites due to cGCP violations significantly underpowered the study, falling short of industry best practices for trial integrity.
• BIV201's room-temperature stable formulation in a pre-filled syringe is a key product differentiation compared to other terlipressin products globally that typically require refrigeration and are not available in a pre-filled syringe format, potentially offering a superior drug delivery system.
• The FDA has never approved any drug specifically for treating ascites, positioning BIV201 to potentially address a significant unmet medical need in a market estimated to exceed $650 million, which is a unique market opportunity compared to highly competitive therapeutic areas.
• The company's financial position, with recurring losses and negative cash flows, raises substantial doubt about its ability to continue as a going concern, which is a common challenge for early-stage biopharmaceutical companies but indicates a high level of financial risk compared to established industry players with diversified revenue streams.

Management Changes

Corporate Governance

Legal Proceedings

• A purported shareholder class action complaint, Eric Olmstead v. BioVie Inc. et al., No. 3:24-cv-00035, was filed on January 19, 2024, in the U.S. District Court for the District of Nevada, naming the company and certain officers as defendants.
• A second, related putative securities class action, Way v. BioVie Inc. et al., No. 2:24-cv-00361, was filed on February 22, 2024, asserting similar claims against the same defendants.
• On April 15, 2024, the court consolidated these two actions under In re BioVie Inc. Securities Litigation, No. 3:24-cv-00035.
• On June 21, 2024, the lead plaintiff filed an amended complaint, alleging material misrepresentations and/or omissions of material fact relating to the company's business, operations, compliance, and prospects, including information related to the NM101 Phase 3 study and trial of bezisterim (NE3107) in mild to moderate probable Alzheimer's Disease, in violation of Sections 10(b) and 20(a) of the Exchange Act, and Rule 10b-5.
• The class action is on behalf of purchasers of the company's securities during the period from December 7, 2022, through November 28, 2023, and seeks unspecified monetary damages, costs, and attorneys' fees.
• The defendants' motion to dismiss the amended complaint was denied on March 27, 2025, allowing the case to move into fact discovery.
• On December 30, 2024, a shareholder derivative lawsuit was filed by putative stockholder Andrew Hulm, allegedly on behalf of the company, piggy-backing on the securities class action and naming certain current and former officers and directors as defendants for alleged breach of fiduciary duties.
• On April 28, 2025, a second shareholder derivative lawsuit was filed by putative stockholder William Settel, also piggy-backing on the securities class action with essentially the same claims.
• The company believes the claims are without merit and intends to defend vigorously against them, but there can be no assurances as to the outcome.
• Insurance coverage for these actions is subject to a $2 million deductible, meaning the company is responsible for the first $2 million of loss (defense costs and damages) before insurance applies.

Related Party Transactions

• Acuitas Group Holdings, LLC, the company's largest stockholder, was involved in previous private placements and warrants, including PIPE Warrant Shares with a 'down round' feature that led to deemed dividends of $325,041 for the three months ended September 30, 2024, and $44,424 for the three months ended December 31, 2024.
• The company is obligated to pay a low single digit royalty on net sales of BIV201 (continuous infusion terlipressin) to be shared among LAT Pharma Members, PharmaIn Corporation, and The Barrett Edge, Inc., pursuant to the April 11, 2016, merger agreement.
• The company is obligated to pay a low single digit royalty on net sales of all terlipressin products covered by US patent no. 9,655,645 and any future foreign issuances, capped at a maximum of $200,000 per year, to the University of Padova (Italy) pursuant to a Technology Transfer Agreement dated July 25, 2016.
• A Director of the Company was paid $50,000 for consulting services during the nine months ended March 31, 2025.

Stakeholder Impact

• Shareholders will experience immediate and substantial dilution from the current public offering, and face potential future dilution from additional capital raises, exercise of outstanding options/warrants, and milestone-based share issuances.
• Existing shareholders are exposed to the risk of further stock price decline and decreased liquidity due to the recent 1-for-10 reverse stock split.
• Shareholders are directly impacted by ongoing securities class action and derivative litigation, which could result in substantial damages and negatively affect the company's stock price.
• Employees, particularly those in the clinical team, have been affected by a reduction in force in December 2023, and their equity awards are subject to vesting terms and potential modifications.
• Future patients stand to benefit from the successful development and approval of the company's drug candidates for neurological/neurodegenerative disorders and advanced liver disease, but delays or failures in clinical trials directly impact their access to these potential treatments.
• Third-party contract research organizations (CROs), clinical trial sites, and manufacturers face scrutiny and potential impact from issues like the cGCP violations identified in the Alzheimer's trial, which could affect their reputation and future engagements.
• Creditors, while the company recently paid off a significant loan, still face increased risk due to the company's 'going concern' warning, indicating ongoing financial instability and dependence on future financing.

Next Steps

• Finalize protocol design for Phase 3 study of BIV201 for ascites.
• Consider employing adaptive trial features or designing a new Phase 3 study for bezisterim in Alzheimer's disease.
• Continue fact discovery in the shareholder class action and derivative lawsuits.
• Secure additional financing through equity sales, loans, or strategic transactions to fund ongoing operations and development.
• Apply to list the Warrants on Nasdaq under the symbol BIVIW.

Key Dates

Recommendation

The filing reveals critical issues that warrant a 'sell' recommendation. The explicit 'going concern' warning, coupled with recurring losses and negative cash flow, indicates severe financial instability. The significant protocol deviations and cGCP violations in the Phase 3 Alzheimer's trial are a major red flag, undermining the credibility of past positive data and creating substantial uncertainty for future development in a key program. Ongoing securities litigation adds further financial and reputational risk. While the company has secured a DOD grant and is pursuing new trials, these positives are heavily outweighed by the fundamental operational and financial challenges, and the need for continuous capital raises that will dilute existing shareholders. The reverse stock split has already negatively impacted share value and liquidity.

Keywords

Biopharmaceutical, Clinical-stage, Drug development, Alzheimer's disease, Parkinson's disease, Long COVID, Liver cirrhosis, Ascites, Bezisterim, NE3107, BIV201, Terlipressin, SEC filing, Public offering, Warrants, Clinical trials, FDA, Orphan Drug, Fast Track, Intellectual property, Going concern, Litigation, Reverse stock split